The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis

Condition(s) targeted: Peri-Implantitis

Intervention: 2.5 mg Chlorhexidine gluconate chip (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Dexcel Pharma Technologies Ltd.

Official(s) and/or principal investigator(s):
Eli Machtei, Prof., Study Chair, Affiliation: Department of Periodontology, School of Graduate Dentistry, Rambam Health Care Center Haifa, Israel, 9602

Overall contact:
Sigalit Melcer, Email: sigalit.melcer@dexcel.com

The objective of the study is to assess the efficacy and safety of PerioChip® (Chlorhexidine gluconate chip) in the treatment of patients with Peri-implantitis. The hypothesis of the study is that PerioChip® in adjunct to mechanical subgingival debridement is more effective in the treatment of peri-implantitis when compared to the common method of mechanical subgingival debridement alone. The primary efficacy measure will be the reduction in probing pocket depth at 6 months as measured at sites of qualifying target implant.

Official title: Multi-Center Phase 3 Trial of Chlorhexidine Gluconate Chip for the Use in Subjects With Peri-Implantitis.

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Absolute change in mean probing Pocket Depth for selected target implants

Secondary outcome:

Absolute change in mean probing Pocket Depth of selected target implants in patients with baseline Pocket Depth measurement of 6-8 mm inclusive

Change in percentage of selected target implants Bleeding on Probing

Absolute change in mean probing Pocket Depth of selected target implants

Detailed description: This is a research study that uses the drug PerioChip® (active ingredient chlorhexidine gluconate) as an experimental treatment for "periimplantitis". This condition is defined an inflammation affecting the tissues (gums and bone) around an already stable implant, resulting in loss of supporting jaw bone. It is caused by many factors but current research links the condition with the presence of bacteria in the mouth which are responsible for periodontitis (gum disease). If left untreated, this can lead to decreased bone support, weakening of the implant and potential lost of the implant. Nonsurgical treatment (deep cleaning with instruments to remove plaque) and rigorous diligent oral care at home are commonly used to treat both periimplantitis (gum disease around an implant) and periodontitis (gum disease around teeth). The medication PerioChip® is a small dental chip (its size is smaller than a match head, and it is completely flat). The chip contains chlorhexidine gluconate, an antimicrobial agent which is not an antibiotic. The chip is inserted into the gum sulcus that is present around the tooth or implant and biodegrades naturally within 7 to 10 days while releasing the medication. The purpose of this study is to determine the efficacy of PerioChip® in addition to a standard deep cleaning treatment regime, as compared to standard deep cleaning alone. in a large patient population, and to collect additional safety data about the treatment.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Good general health

- At least one implant in the oral cavity with clinical and radiographical signs of

peri-implantitis. Including bone loss in combination with bleeding and/or suppuration on probing and a peri-implant Probing Depth (PD) of 5-8 mm.

- The implants have been in function for more than 2 years.

- Fixed prosthetic restoration of the implant.

Exclusion Criteria:

- Pregnancy.

- Patient uses Chlorhexidine oral rinses/ mouthwashes on a regular basis.

- Allergic reaction to Chlorhexidine.

- Active Periodontitis which required definitive treatment.

- Presence of orthodontic appliances, or any removable appliances, that impinges on

the tissues being assessed.

- Use of systemic antibiotic therapy and/or chronically use of non-steroidal

anti-inflammatory drugs (NSAIDs).

- Uncontrolled diabetes, of any type.

Sigalit Melcer, Email: sigalit.melcer@dexcel.com

Zentrum für Zahn,- Mund- und Kieferheilkunde Poliklinik für Parodontologie, Giessen 35392, Germany; Recruiting
Jörg Meyle, Prof., Phone: 0641/99-46191

Department of Periodontology, School of Graduate Dentistry, Rambam Health Care Center, Haifa 9602, Israel; Recruiting
Eli Machtei, Prof., Principal Investigator

The Harvard School of Dental Medicine, Boston, Massachusetts 02115, United States; Recruiting
David Kim, Dr., Phone: 617-432-1472

Starting date: July 2014
Last updated: February 15, 2015